Please assess the completion status of the following clinical trial:

Trial Title: Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed solid tumor malignancy AND hypertension, defined as a systolic pressure \> 130 OR a diastolic pressure \> 80~* Patients cannot be on active chemotherapy or radiation therapy; start of treatment with ACE-I or ARB must occur at least four weeks after the last dose of chemotherapy or radiation therapy~* Creatinine \< 2.5~* Potassium \< ULN~* Ability to understand and the willingness to sign a written informed consent document~* HIV positive patients are eligible to participate in this study~Exclusion Criteria:~* Patients who are pregnant or nursing due to significant risk to the fetus/infant~* Patients who are unable to take oral medications~* Patients who are currently taking an ACE-Inhibitor or ARB

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral benazepril hydrochloride once daily on days 1-7.
- Arm II (Type: EXPERIMENTAL): Patients receive oral lisinopril once daily on days 1-7.
- Arm III (Type: EXPERIMENTAL): Patients receive oral ramipril twice daily on days 1-7.
- Arm IV (Type: EXPERIMENTAL): Patients receive oral losartan potassium once daily on days 1-7.

Based on this trial design, predict the completion outcome and termination type (if applicable).